Skip to main content
Clinical Trials/ITMCTR2200005698
ITMCTR2200005698
Not yet recruiting
Phase 1

Clinical observation of Fascia Manipulation in the treatment of visual display terminal asthenopia

Guangzhou Medical University0 sitesTBD

Overview

Phase
Phase 1
Intervention
Not specified
Conditions
Video terminal visual fatigue, pseudo-myopia, low-level myopia
Sponsor
Guangzhou Medical University
Status
Not yet recruiting
Last Updated
3 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
3 years ago
Study Type
Interventional study
Sex
All

Investigators

Sponsor
Guangzhou Medical University

Eligibility Criteria

Inclusion Criteria

  • 1\. Aged 18\-25 years, no gender limit;
  • 2\. Meet the VDT diagnostic criteria;
  • 3\. Those without organic lesions of the eyes and head;
  • 4\. Those who have not been treated or have been treated with other drugs for more than 2 weeks;
  • 5\. Proficient in the use of smart phones;
  • 6\. Those who signed the informed consent;
  • 7\. No history of head trauma or surgery.

Exclusion Criteria

  • 1\. Subjects with poor compliance;
  • 2\. Subjects with serious diseases (such as diabetes, liver and kidney disease and (or) heart disease, thyroid disease, adrenal disease);
  • 3\. Those with other eye diseases (such as infectious conjunctivitis, glaucoma);
  • 4\. Subjects diagnosed with presbyopia (the dominant eye's controlled width is less than 2\.5 diopters (D));
  • 5\. Subjects with uncorrected severe refractive errors in the dominant eye;
  • 6\. Subjects who have undergone ophthalmic surgery;
  • 7\. Subjects whose dominant eye can achieve the best corrected visual acuity advantage \<1\.0;
  • 8\. Subjects with serious diseases (such as diabetes, liver disease, kidney disease and (or) heart disease, thyroid disease, adrenal disease);
  • 9\. Subjects who often take drugs or health food that may have an effect on the eyes or are expected to use related drugs or health food during the study period;
  • 10\. Subjects who may cause drug allergy;

Outcomes

Primary Outcomes

Not specified

Similar Trials